Intersect ENT (XEXT) Stock Gains After Upsizing Secondary Offering

NEW YORK (TheStreet) -- Intersect ENT  (XENT) shares are climbing 2.5% to $25.79 in trading on Wednesday after the commercial stage drug device company upsized its secondary offering by 582,000 shares to 3.582 million shares.

The company priced its offering at $25 per share, a slight decrease from yesterday's closing price of $25.16, resulting in aggregate proceeds of $89.6 million.

J.P. Morgan (JPM) and Bank of America/Merrill Lynch (BAC) are acting as joint book-running managers for the offering.

XENT Chart XENT data by YCharts

More from Markets

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers